Effects of TNF-Alpha Inhibitors on Circulating Th17 Cells in Patients Affected by Severe Psoriasis

Drug Development Research

Volumn 75, Issue , 2014, Pages S73-S76

  Piaserico, Stefano ^a   Sandini, Elena ^a   Saldan, Alda ^a   Abate, Davide ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

PASI; psoriasis; Th17; tumor necrosis factor (TNF) alpha inhibitors

Indexed keywords

ADALIMUMAB; ETANERCEPT; INTERLEUKIN 17; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGED; BIOLOGICAL THERAPY; BLOOD SAMPLING; CLINICAL ARTICLE; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; LYMPHOCYTE COUNT; MALE; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; REVIEW; SKIN; TH17 CELL; TREATMENT DURATION; TREATMENT RESPONSE; UNIVERSITY HOSPITAL; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; CYTOLOGY; DRUG EFFECTS; IMMUNOLOGY; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; IMMUNOGLOBULIN G; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; TH17 CELLS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84910050292     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.21202     Document Type: Review

References (11)

1. Antiga E, Volpi W, Cardilicchia E, Maggi L, Filì L, Manuelli C, Parronchi P, Fabbri P, Caproni M,. 2012. Etanercept downregulates the Th17 pathway and decreases the IL-17+/IL-10+ cell ratio in patients with psoriasis vulgaris. J Clin Immunol 32: 1221-1232.
2. Balato A, Schiattarella M, Di Caprio R, Lembo S, Mattii M, Balato N, Ayala F,. 2013. Effects of adalimumab therapy in adult subjects with moderate-to-severe psoriasis on Th17 pathway. J Eur Acad Dermatol Venereol Sep 4, doi: 10.1111/jdv.12240. [Epub ahead of print].
3. Chen D, Chen Y, Chen H, Hsieh C, Lin C, Lan J,. 2011. Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-α therapy. Arthritis Res Ther 13: R126.
4. Elloso MM, Gomez-Angelats M, Fourie AM,. 2012. Targeting the Th17 pathway in psoriasis. J Leukoc Biol 92: 1187-1197.
5. Lowes MA, Suárez-Fariñas M, Krueger JG,. 2014. Immunology of psoriasis. Annu Rev Immunol 32: 227-255.
6. Lynde CW, Poulin Y, Vender R, Bourcier M, Khalil S,. 2014. Interleukin 17A: Toward a new understanding of psoriasis pathogenesis. J Am Acad Dermatol 71: 141-150.
7. Kagami S, Rizzo HL, Lee JJ, Koguchi Y, Blauvelt A,. 2009. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol 130: 1373-1383.
8. Szalay B, Mészáros G, Cseh Á, Ács L, Deák M, Kovács L, Vásárhelyi B, Balog A,. 2012. Adaptive immunity in ankylosing spondylitis: phenotype and functional alterations of T-cells before and during infliximab therapy. Clin Dev Immunol 2012: 808724.
9. Szalay B, Vásárhelyi B, Cseh Á, Tulassay T, Deák M, Kovács L, Balog A,. 2014. The impact of conventional DMARD and biological therapies on CD4 cell subsets in rheumatoid arthritis: a follow-up study. Clin Rheumatol 33: 175-185.
10. Zaba LC, Suárez-Fariñas M, Fuentes-Duculan J, Nograles KE, Guttman-Yassky E, Cardinale I, Lowes MA, Krueger JG,. 2009. Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. J Allergy Clin Immunol 124: 1022-10.
11. Zhang L, Yang X, Cheng J, Hui R, Gao T,. 2010. Increased Th17 cells are accompanied by FoxP3(+) treg cell accumulation and correlated with psoriasis disease severity. Clin Immunol 135: 108-117.